H. 976
2015-2016 Session: Convene: 1/7/15 and Adjourn: 1/4/17

3/10/15: House Referred to committee on Health Care Financing.

BioPharma: NC introduces biosimilar substitution bill as MA looks to amend its law

March 12

North Carolina is jumping on the biosimilar substitution legislation bandwagon with a new bill unveiled this week, while Massachusetts is looking to slightly tweak its law.

Read full article here.

 

• Bill Information

  Expands the definition of “interchangeable biological product” to include biologics that are determined by FDA to be “therapeutically equivalent” to the prescribed biologic.

• Archive

  Business of Biosimilars and Biobetters

  June 16, 2011

  September 19-21, 2011 Seaport World Trade Center Boston, MA Read More

  Business of Biosimilars and Biobetters

  June 16, 2011

  September 19-21, 2011 Seaport World Trade Center Boston, MA Read More

  4th Annual International Partnering Conference – BioPharm America

  June 16, 2011

  September 7-9, 2011 Westin Boston Waterfront Boston, MA Read More

  4th Annual International Partnering Conference – BioPharm America

  June 16, 2011

  September 7-9, 2011 Westin Boston Waterfront Boston, MA Read More

  The 4th Massachusetts Life Sciences Innovation Day

  June 16, 2011

  June 2, 2011 Harvard Club of Boston, 374 Commonwealth Avenue Boston, MA Read More

  Follow-on Biologics: Current Trends and Insights


  June 16, 2011

  March 7, 2011 Federal Reserve Bank of Boston; New England Room Boston, MA Read More

  MassBio Federal Policy White Paper – 2009

  June 16, 2011

  MassBio is front and center on Capitol Hill when it comes to advocating for policies that will pave the way for innovation. We fight for the laws and regulations that will speed the development of treatments and cures for Alzheimer’s, Diabetes, HIV/AIDs and other ailments. We work for policies that will help bring those drugs to […]

  MassBio – Biosimilars – Our View

  June 16, 2011

  Drugs developed through biotechnology differ from traditional small molecule chemical drugs. They are “biologics” that are complex medicines manufactured using living organisms. Biosimilars, also known as follow-on biologics are products that are similar to, but not the same as, an innovative new drug. They are not generic drugs, which are products shown to be the […]

  Massachusetts Government – Life Sciences

  June 16, 2011

  From pharmaceuticals and medical devices to diagnostics and biotechnology, the life sciences are a cornerstone of Massachusetts’ innovation economy.  Massachusetts is a global leader in the life sciences, thanks to our world-class academic institutions and medical centers, our talented workforce, and our industry-sector leading companies. Read More

  Massachusetts Government – Life Sciences

  June 16, 2011

  From pharmaceuticals and medical devices to diagnostics and biotechnology, the life sciences are a cornerstone of Massachusetts’ innovation economy.  Massachusetts is a global leader in the life sciences, thanks to our world-class academic institutions and medical centers, our talented workforce, and our industry-sector leading companies. Read More